News & Updates

Show Multimedia Only
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

TKI-ICI combo offers hope for prostate cancer patients with poor prognosis

29 Feb 2024 byAudrey Abella

A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.

29 Feb 2024